AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$HIMS

Boughton Soleil sold $96K of HIMS

Boughton Soleil (Chief Legal Officer) sold 3,462 shares of Hims & Hers Health, Inc. (HIMS) at $27.60 on 2026-10-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Boughton Soleil
Published Oct 29, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HIMS
Neutral
medium confidence
Mentioned
$HIMS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HIMSNeutralLow
01

Why it matters

While the transaction size is modest, it provides a data point for monitoring insider sentiment.

02

Market read

Primary source filing; small insider sale with limited market impact.

03

What to watch

The 10b5-1 plan indicates pre‑arranged execution, reducing the informational value of the sale.

Relevance 2/10Novelty 2/10Timing: after-hours filing on 2026-10-28

Background

SEC Form 4 filing discloses an insider transaction by Hims & Hers Health's chief legal officer.

Company-level read

Ticker impact

$HIMSNeutralMedium confidence
Context

Chief Legal Officer Boughton Soleil sold 3,462 HIMS shares for $95,551 at $27.60 per share via a 10b5-1 plan.

Expected impact

likely slight downward pressure as the market prices the insider sale

Evidence & confidence

C‑level insider selling, even in modest size, is often viewed as a negative signal, but the amount ($96K) is small relative to market cap.

Market effects

Sector

Minimal impact on the broader telehealth sector.

Regional

No regional effect beyond HIMS shareholders.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing unrelated to company outlook.

Key entities

  • person
    Boughton Soleil

    Chief Legal Officer of Hims & Hers Health, Inc.

  • company
    Hims & Hers Health, Inc.

    US‑listed telehealth company (ticker HIMS).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HIMS insider trading history →

Related articles

$HIMSHighAI 8/10

Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses “Enforcement Discretion” to Open Peptide Compounding

Hims & Hers Health (HIMS) shares rose 6% after HHS announced enforcement discretion for six peptides, potentially benefiting Hims' peptide facility. The company awaits final FDA rules for a full launch. Hims' gross margin fell to 63.8% in Q2, with Q3 results on Nov. 9. Analysts estimate the peptide market at $2.2B-$3.3B, and Hims' revenue at $4.49B by 2028.

finance.yahoo.com
$HIMSMed

Hims Seeks Dismissal of FTC Suit Over User Data, Subscriptions

Hims & Hers Health Inc. asked a California judge to dismiss an FTC lawsuit alleging deceptive practices, improper data sharing, and difficult subscription cancellations. The company claims its privacy policy is clear and the FTC misapplied federal law. The FTC argues Hims violated a 2010 law requiring clear disclosure of subscription terms. Hims has 2.6 million subscribers. A hearing is scheduled for January 7.

claimsjournal.com